Transgenic Goat Antithrombin Gains EU Nod
This article was originally published in The Pink Sheet Daily
Executive Summary
GTC Biotherapeutics' recombinant human antithrombin ATryn was granted European Union marketing authorization roughly six months after receiving an initial negative opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use
You may also be interested in...
GTC Completes BLA For Recombinant Clot Buster Atryn
Phase II study in sepsis DIC indication is actively enrolling, GTC says.
GTC Completes BLA For Recombinant Clot Buster Atryn
Phase II study in sepsis DIC indication is actively enrolling, GTC says.
GTC Anticipates Reaching U.S. Market In 2009 With Human Antithrombin ATryn
Company tells “The Pink Sheet” DAILY it will seek indications for larger patient populations than initial target of hereditary antithrombin deficiency.